3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder

Tuesday July 23rd, 2019 | General

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organisation (CDMO) specialized in the process development and GMP manufacturing of biologics announces Keensight Capital, one of the European leading players in Growth Buyout, specialist in the IT and Healthcare sectors, as its new major investor. The incorporation of this new main shareholder comes after INFARCO, […]

3P Biopharmaceuticals_Betalutin

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

Wednesday June 26th, 2019 | General

3P Biopharmaceuticals (3P) and Norwegian biopharmaceutical company Nordic Nanovector have extended their collaboration agreement for the biopharmaceutical development of Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment. The non-Hodgkin lymphoma (NHL) is cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. 3P and Nordic Nanovector started their […]

Large-scale manufacturing process for Strangvac now secured

Tuesday April 2nd, 2019 | General

We are so glad to be part of such an exciting project with the Swedish company INTERVACC, who we are working with on manufacturing of Strangvac® including the large-scale production of the vaccine against equine strangles. The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, secured large-scale production of the […]

Expansion of analytical capacities by 3P Biopharmaceuticals

Wednesday February 27th, 2019 | General

3P Biopharmaceuticals has recently increased its analytical capacities and capabilities.   The 3P Analytical Development Area is one of the company’s core competences and is crucial to the state-of-the-art technologies as well as services it provides to the clients.   The development of analytical methods is an essential activity in any process development and manufacturing […]

3P Biopharmaceuticals incorporates a LIMS, a Laboratory Information Management Systems

Monday June 25th, 2018 | General

3P Biopharmaceuticals is incorporating a new Laboratory Information Management Systems (LIMS) from Abbott Informatics, a global leader provider of laboratory solutions. The implementation phase is currently in progress together with Abbott Informatics who are also ensuring the specific training required for the completion of each milestone. LIMS is a comprehensive solution that improves quality and […]

3P Biopharmaceuticals and Viscofan to collaborate in an innovate advanced therapy project

| General

Cardiomesh is the project in which 3P Biopharmaceuticals and Viscofan are collaborating to develop and manufacture an innovative cell therapy product. 3P Biopharmaceuticals has executed the tuning, the process validation and the GMP manufacturing for clinical use. 3P Biopharmaceuticals, a CDMO specialized in the process development and GMP manufacturing of biologics and cell therapy products, […]